Issue 10, 2025

Development and in vitro and ex vivo characterization of a twin nanoparticulate system to enhance ocular absorption and prolong retention of dexamethasone in the eye: from lab to pilot scale optimization

Abstract

Conventional eye drops show low bioavailability (below 20%) due to the eye's inherent tissue barriers and unique microenvironment. Recent advancements in pharmaceutical nanotechnology have explored various nanoparticle systems, such as micelles, liposomes, and nanoemulsions, to enhance corneal permeation and prolong drug retention. In this study, we propose a twin nanoparticulate system, combining the advantages of two nanoparticles to improve drug targeting and therapeutic efficacy. A dexamethasone-loaded liposome–microemulsion (LME) twin nanoparticulate system was developed using high-pressure homogenization and successfully scaled up. Both liposomes and microemulsions were of similar size (∼60 nm) and displayed uniform distribution (polydispersity index < 0.2) upon combination. The final formulation was hypo-osmolar (osmolality < 100 mOsm per Kg), making it ideal for dry eye relief. Drug release was extended for up to 8 h, following a non-Fickian diffusion pattern. The LME formulation, tested under different conditions (2–8 °C and 25 °C with 60% relative humidity), was found to be stable for 6 months. It showed no cytotoxicity in human corneal epithelial cells up to 10 μM drug concentration. Fluorescence microscopy revealed rapid nanoparticle uptake by cells within 5 minutes. Human corneal epithelial cells showed a marked reduction in inflammatory biomarkers (IL-6, IL-8, and TNF-α) after drug-loaded LME treatments, compared to the control. Corneal tissue imaging confirmed prolonged retention of nanoparticles within the tissue. A whole eye ex vivo permeation study demonstrated higher drug concentrations in the aqueous humour of LME drug-treated rabbit eyes compared to a reference product. This twin nanoparticulate system, loaded with dexamethasone, offers a promising next-generation treatment for dry eye disease (DED).

Graphical abstract: Development and in vitro and ex vivo characterization of a twin nanoparticulate system to enhance ocular absorption and prolong retention of dexamethasone in the eye: from lab to pilot scale optimization

Associated articles

Supplementary files

Article information

Article type
Paper
Submitted
31 Dec 2024
Accepted
26 Mar 2025
First published
23 Apr 2025
This article is Open Access
Creative Commons BY-NC license

Nanoscale Adv., 2025,7, 3125-3142

Development and in vitro and ex vivo characterization of a twin nanoparticulate system to enhance ocular absorption and prolong retention of dexamethasone in the eye: from lab to pilot scale optimization

M. Sarfraz, G. Behl, S. Rani, N. O'Reilly, P. McLoughlin, O. O'Donovan, A. L. Reynolds, J. Lynch and L. Fitzhenry, Nanoscale Adv., 2025, 7, 3125 DOI: 10.1039/D4NA01086H

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements